In June 2010, we entered into an exclusive worldwide collaboration with Abbott to develop and commercialize elagolix and all next-generation gonadotropin-releasing hormone (GnRH) antagonists (collectively, GnRH Compounds) for women’s and men’s health. Under the terms of our agreement with Abbott, we and Abbott will work jointly to advance GnRH Compounds towards commercialization. Abbott is responsible for all development, marketing, and commercialization costs and will be entitled to a percentage of worldwide sales of GnRH Compounds.
In June 2010, we entered into a worldwide collaboration with Boehringer Ingelheim to research, develop and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Under the terms of the agreement, we and Boehringer Ingelheim will work jointly to identify and advance GPR119 agonist candidates into pre-clinical development. Boehringer Ingelheim will then be responsible for the global development and commercialization of potential GPR119 agonist products. We will be entitled to a percentage of any future worldwide sales of GPR119 agonists resulting from the collaboration.
In July 2001, we entered into a worldwide collaboration with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological and gastrointestinal diseases. Under the terms of this agreement, GSK sponsored and we jointly conducted a collaborative research program and collaborated in the development of our current lead compounds, as well as novel back-up candidates and second generation compounds identified through the collaborative research. The sponsored research portion of this collaboration agreement concluded in 2005. We will be eligible to receive milestone payments as compounds progress through the research and development process, royalties on future product sales and co-promotion rights in the U.S. in some circumstances.
Dainippon Sumitomo Pharma Co. Ltd.
In October 2007, we announced an exclusive license agreement with Dainippon Sumitomo Pharma Co. Ltd. (DSP) to develop and commercialize indiplon in Japan. Under the terms of the agreement DSP is responsible for all development, marketing and commercialization costs of indiplon in Japan. We will be eligible to receive milestone payments upon specified future events related to the development and commercialization of indiplon in Japan. We are also entitled to royalties from DSP on future sales of indiplon in Japan.